Proteomics International Partners With University of Oxford to Advance Endometriosis Study
Predictive diagnostics specialist Proteomics International Laboratories (ASX: PIQ) has signed an agreement with the University of Oxford to acquire approximately 600 patient plasma samples for a study into endometriosis.
Proteomics International Signs Agreement With University of Oxford for Endometriosis Study
Proteomics International Laboratories (ASX:PIQ) has partnered with the University of Oxford to acquire approximately 600 patient plasma samples for further clinical validation of its PromarkerEndo blo
Proteomics Says PromarkerD's US Launch Delayed
Proteomics International Laboratories (ASX:PIQ) said the US roll out of its PromarkerD predictive test for diabetic kidney disease, originally planned for Q2 of 2024, is now "likely to be delayed," ac
Proteomics International Laboratories Downgraded to Hold From Speculative Buy by Morgans
Proteomics International Laboratories Downgraded to Hold From Speculative Buy by Morgans
Proteomics International Laboratories Secures ISO 13485 Certification Renewal
Medical technology company Proteomics International Laboratories (ASX:PIQ) secured ISO 13485 recertification, which is valid for three years, according to a filing with the Australian Securities Excha
Proteomics International Laboratories Narrows Fiscal H1 Loss
Proteomics International Laboratories (ASX:PIQ) reported Friday a net loss of AU$3.8 million in the six months ended Dec. 31, 2023, narrowing from AU$4.0 million a year earlier. Loss per share remaine
Proteomics International's Blood Test for Throat Cancer Undergoes Biomarker Validation
Proteomics International Laboratories (ASX:PIQ) said a panel validated the biomarkers for the company's novel PromarkerEso blood test for esophageal adenocarcinoma. The blood test targets both esophag
Proteomics International Laboratories Raises AU$6.5 Million for Test Commercialization, Further Development; Shares Down 10%
Proteomics International Laboratories (ASX:PIQ) raised AU$6.5 million via an institutional placement of 8.6 million ordinary shares at AU$0.76 each. Proceeds will be used to commercialize the Promarke
Is Proteomics International Laboratories (ASX:PIQ) In A Good Position To Invest In Growth?
Proteomics Signs Deal to Sell PromarkerD in Chile; Shares Jump 5%
Proteomics International Laboratories (ASX:PIQ) entered into a licensing agreement for the distribution of the diabetic kidney disease blood test system PromarkerD in Chile, the medical technology com
Proteomics International Laboratories Receives More Than AU$1.8 Million R&D Tax Rebate
Proteomics International Laboratories (ASX:PIQ) received a research and development tax incentive of more than AU$1.8 million for 2022-23, according to a Thursday news release. Shares of the medical t
Proteomics International Price Target Raised 46% to A$2.42/Share by Morgans
Proteomics International Price Target Raised 46% to A$2.42/Share by Morgans
Proteomics International Price Target Raised 11% to A$2.00/Share by Euroz Hartleys
Proteomics International Price Target Raised 11% to A$2.00/Share by Euroz Hartleys
Proteomics International Laboratories Limited's (ASX:PIQ) Shift From Loss To Profit
Proteomics International Laboratories Requests Extension of Securities Trading Suspension
Proteomics International Laboratories' (ASX:PIQ) has requested the Australian bourse to extend the voluntary suspension of its securities pending an announcement related to a regulatory approval appli
Proteomics International (ASX:PIQ) to Present New Oesophageal Cancer Test at Global Conference
Proteomics International Subsidiary Secures New Patent in Japan; Shares Fall 4%
Proteomics International Laboratories' (ASX:PIQ) subsidiary, OxiDx, secured a patent in Japan for its platform technology to measure oxidative stress, the diagnostic firm said on Monday. The patent si
Proteomics International Target Price Cut 6.2% to A$1.66/Share by Morgans>PIQ.AU
Proteomics International Target Price Cut 6.2% to A$1.66/Share by Morgans>PIQ.AU
Investing in Proteomics International Laboratories (ASX:PIQ) Five Years Ago Would Have Delivered You a 329% Gain
Proteomics International (ASX:PIQ) Inks Exclusive Licence Agreement to Bring PromarkerD to the US Market
No Data